<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kaid C</submitter><funding>FAPESP-CEPID</funding><funding>CNPq</funding><funding>INCT-CETGEN</funding><funding>FINEP-CTC</funding><funding>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil</funding><funding>FAPESP, São Paulo</funding><pagination>1276-1286</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7210722</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(5)</volume><pubmed_abstract>Malignant brain tumors are among the most aggressive cancers with poor prognosis and no effective treatment. Recently, we reported the oncolytic potential of Zika virus infecting and destroying the human central nervous system (CNS) tumors in vitro and in immunodeficient mice model. However, translating this approach to humans requires pre-clinical trials in another immunocompetent animal model. Here, we analyzed the safety of Brazilian Zika virus (ZIKV&lt;sup>BR&lt;/sup>) intrathecal injections in three dogs bearing spontaneous CNS tumors aiming an anti-tumoral therapy. We further assessed some aspects of the innate immune and inflammatory response that triggers the anti-tumoral response observed during the ZIKV&lt;sup>BR&lt;/sup> administration in vivo and in vitro. For the first time, we showed tha</pubmed_abstract><journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal><pubmed_title>Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors.</pubmed_title><pmcid>PMC7210722</pmcid><funding_grant_id>2013/08028-1</funding_grant_id><funding_grant_id>0108057900</funding_grant_id><funding_grant_id>573633/2008-8</funding_grant_id><funding_grant_id>309206/2011-1; 444722/2014-9</funding_grant_id><funding_grant_id>2018/16213-7</funding_grant_id><pubmed_authors>Tanioka RKO</pubmed_authors><pubmed_authors>Ferreira LCS</pubmed_authors><pubmed_authors>Astray R</pubmed_authors><pubmed_authors>Pires CG</pubmed_authors><pubmed_authors>Goulart E</pubmed_authors><pubmed_authors>Barbosa IN</pubmed_authors><pubmed_authors>Okamoto OK</pubmed_authors><pubmed_authors>Madi RADS</pubmed_authors><pubmed_authors>de Andrade TO</pubmed_authors><pubmed_authors>Massoco CO</pubmed_authors><pubmed_authors>Caires-Junior LC</pubmed_authors><pubmed_authors>Castro-Amarante MF</pubmed_authors><pubmed_authors>Kaid C</pubmed_authors><pubmed_authors>Mitsugi TG</pubmed_authors><pubmed_authors>Pereira LR</pubmed_authors><pubmed_authors>Moreno ACR</pubmed_authors><pubmed_authors>Pereira MCL</pubmed_authors><pubmed_authors>Zatz M</pubmed_authors><pubmed_authors>Porchia BFMM</pubmed_authors><pubmed_authors>Landini V</pubmed_authors><pubmed_authors>Sanches DS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors.</name><description>Malignant brain tumors are among the most aggressive cancers with poor prognosis and no effective treatment. Recently, we reported the oncolytic potential of Zika virus infecting and destroying the human central nervous system (CNS) tumors in vitro and in immunodeficient mice model. However, translating this approach to humans requires pre-clinical trials in another immunocompetent animal model. Here, we analyzed the safety of Brazilian Zika virus (ZIKV&lt;sup>BR&lt;/sup>) intrathecal injections in three dogs bearing spontaneous CNS tumors aiming an anti-tumoral therapy. We further assessed some aspects of the innate immune and inflammatory response that triggers the anti-tumoral response observed during the ZIKV&lt;sup>BR&lt;/sup> administration in vivo and in vitro. For the first time, we showed tha</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 May</publication><modification>2026-04-08T06:36:56.912Z</modification><creation>2022-02-10T09:14:59.132Z</creation></dates><accession>S-EPMC7210722</accession><cross_references><pubmed>32220305</pubmed><doi>10.1016/j.ymthe.2020.03.004</doi></cross_references></HashMap>